News & Events – Ysios Capital

Ysios Capital ESG Report

20 Nov 2024

Ysios Capital ESG Report

Upcoming events

Bio-Neuroscience
25 - 27 February 2025
Amsterdam
18th Annual European Life Sciences CEO Forum
26 - 27 February 2025
Zurich

Type:

Year:

SparingVision advances PRODYGY trial into Phase II following positive DSMB recommendation

DSMB confirms favorable safety profile of SPVN06 across all three doses in patients with severe advanced rod-cone dystrophy (RCD)(n=9)

Mineralys Therapeutics Announces Phase 2 Clinical Trial of Lorundrostat for Obstructive Sleep Apnea in Patients with Hypertension<

Mineralys Therapeutics Announces Phase 2 Clinical Trial of Lorundrostat for Obstructive Sleep Apnea in Patients with Hypertension

Estimated 54 million people suffer from obstructive sleep apnea in the U.S.

Anaconda Biomed Appoints Trent Reutiman New CEO

Seasoned Medtech Executive to Expand Company Presence Into U.S.

Xeltis announces completion of enrolment in EU Pivotal Trial for aXess and prepares for market approval<

Xeltis announces completion of enrolment in EU Pivotal Trial for aXess and prepares for market approval

Primary endpoint readouts anticipated in Q2 2025, first market approval expected in 2026

Kynexis Announces Positive Topline Results from Phase 1 Study of KYN-5356, a Potential Treatment for Cognitive Impairment Associated with Schizophrenia<

Kynexis Announces Positive Topline Results from Phase 1 Study of KYN-5356, a Potential Treatment for Cognitive Impairment Associated with Schizophrenia

Clinical trial in patients anticipated to begin in 2025

SpliceBio Announces U.S. FDA IND Clearance of SB-007 to Commence Phase 1/2 Clinical Study in Patients with Stargardt Disease<

SpliceBio Announces U.S. FDA IND Clearance of SB-007 to Commence Phase 1/2 Clinical Study in Patients with Stargardt Disease

Phase 1/2 ASTRA study set to begin in the first half of 2025.

Leriglitazone has met the primary endpoint in NEXUS, the pivotal trial for pediatric patients with cerebral Adrenoleukodystrophy<

Leriglitazone has met the primary endpoint in NEXUS, the pivotal trial for pediatric patients with cerebral Adrenoleukodystrophy

Submission of European marketing authorization application (MAA) for leriglitazone expected mid-2025.

Neurona Therapeutics Presents Positive Clinical Update: New Data from NRTX-1001 Cell Therapy Trial in Drug-resistant Epilepsy Announced at 2024 Annual Meeting of the American Epilepsy Society

FDA granted RMAT designation in 2024; pivotal trial planned for 2H 2025

QIAGEN Strengthens QIAstat-Dx With New Barcelona Site to Drive Growth in Infectious Diseases and Precision Medicine Testing<

QIAGEN Strengthens QIAstat-Dx With New Barcelona Site to Drive Growth in Infectious Diseases and Precision Medicine Testing

Site in Esplugues de Llobregat to serve as an innovation hub for QIAstat-Dx

Adcendo ApS Completes Oversubscribed $135 Million Series B Financing to Advance First- in-class ADC Pipeline<

Adcendo ApS Completes Oversubscribed $135 Million Series B Financing to Advance First- in-class ADC Pipeline

Proceeds will be used to support the advancement of multiple first-in-class ADC programs into the clinic and through clinical proof of concept

1 2 3 … 66 Next »

rabbywallet offers a seamless, secure solution for managing digital assets. With its intuitive design, it ensures fast transactions and robust security for all your cryptocurrency needs. Получите максимальное удовольствие от игры и высокие шансы на выигрыш, посетив Joycasino, где вас ждут лучшие слоты, щедрые бонусы и невероятные возможности для выигрыша! The phantom wallet is a popular crypto wallet offering fast, secure, and easy access to your digital assets and decentralized applications.